Short Interest in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Expands By 26.1%

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) saw a large growth in short interest in December. As of December 15th, there was short interest totaling 125,539 shares, a growth of 26.1% from the November 30th total of 99,564 shares. Based on an average daily volume of 111,335 shares, the short-interest ratio is presently 1.1 days. Currently, 2.6% of the shares of the stock are sold short. Currently, 2.6% of the shares of the stock are sold short. Based on an average daily volume of 111,335 shares, the short-interest ratio is presently 1.1 days.

Evaxion A/S Trading Down 0.2%

EVAX opened at $4.77 on Friday. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $12.15. The firm has a 50-day moving average price of $5.58 and a two-hundred day moving average price of $4.22. The stock has a market capitalization of $39.78 million, a PE ratio of -12.23 and a beta of 0.29.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evaxion A/S in a research report on Tuesday, October 14th. Jones Trading raised shares of Evaxion A/S to a “strong-buy” rating in a research note on Wednesday, October 29th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Evaxion A/S in a report on Monday, October 20th. Edward Jones initiated coverage on Evaxion A/S in a report on Thursday, October 30th. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Lake Street Capital increased their price target on Evaxion A/S from $6.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.33.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.